SCHEMBL4814648

SCHEMBL4814648

COc1ccc(C(c2ccc(OC)cc2)n2nc(-c3ccc(CO)s3)c3c2-c2ccccc2C3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 4/20 0.33
TSHR P16473 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
MPI P34949 1/20 0.33
RPS6KB2 Q9UBS0 1/20 0.33
MAPK1 P28482 3/20 0.33
GAA P10253 2/20 0.33
HIF1A Q16665 2/20 0.32
APAF1 O14727 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
EPAS1 Q99814 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.31
RAB9A P51151 3/20 0.31
MAPT P10636 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807369 0.91 CYP2C19 (0.33) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL4808567 0.87 KDR (0.36) KDM4ETSHRALDH1A1HPGDMPI
SCHEMBL4817962 0.84 HIF1A (0.33) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL4814467 0.83 KDR (0.38) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL4819088 0.83 CASR (0.35) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL4816278 0.83 KDR (0.43)
SCHEMBL4817411 0.82 SMN1; SMN2 (0.40) TSHRMAPK1HIF1AEPAS1SMN1; SMN2
SCHEMBL4808580 0.81 TSHR (0.33) MEN1KMT2AKDM4ETSHRALDH1A1
SCHEMBL4817927 0.80 KDR (0.48) MEN1KMT2ARAB9ANPC1
SCHEMBL4808198 0.80 KDM5B (0.41) MEN1KMT2AKDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 MEN1 3383/4885KMT2A 1384/4885KDM4E 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.